Cannabis and Performance: Peer-Reviewed Research Consensus

77 studies analyzedLast updated March 7, 2026

Overview

The research base for cannabis and performance includes 77 peer-reviewed studies spanning 2001–2026. Of these, 7 provide strong evidence, including 1 meta-analyses and 7 randomized controlled trials. Key findings with strong support include: rigorous crossover trial found cbd at 50 mg and 300 mg did not improve or impair running performance, mood, or perceived exertion in trained athletes, and large national survey finds cannabis users are 24% more likely to be physically active, with the strongest association in states with legal recreational cannabis. However, several findings remain debated, and the evidence is not uniform across all areas. Many studies have methodological limitations including small sample sizes, short follow-up periods, and reliance on self-reported data.

What the Research Shows

Findings supported by multiple peer-reviewed studies. Stronger evidence means more consistency across study types.

Rigorous crossover trial found CBD at 50 mg and 300 mg did not improve or impair running performance, mood, or perceived exertion in trained athletes

Strong Evidence
1 study|Acute single-dose design; chronic CBD use effects not assessed. Sample of trained runners may not generalize to other athletes or recreational exercisers. Three conditions in crossover design may not

Large national survey finds cannabis users are 24% more likely to be physically active, with the strongest association in states with legal recreational cannabis

Moderate Evidence
7 studies|Based on limited number of strong-evidence studies.

Where Scientists Disagree

Areas where research shows conflicting results or ongoing scientific debate.

Study found cannabis users had lower alertness and slower cognition in work-related testing but did not report more workplace errors, with effects showing "hangover" and fatigue-related patterns

Moderate Evidence
12 studies|Self-reported workplace errors may not accurately capture actual performance differences. Cannabis use patterns were not precisely controlled or verified. The sample size is not specified in the abstr

Review found THC is generally performance-impairing despite WADA prohibition, with impaired reaction time, coordination, and strength, contrasting with caffeine's clear ergogenic effects

Moderate Evidence
12 studies|Narrative review may not capture all relevant studies. THC effects vary by dose, timing, tolerance, and individual sensitivity. Most exercise-THC studies were conducted in non-athletes. The specific c

Systematic review found that exercise, massage, acupuncture, several medication classes, and lifestyle factors all upregulate the endocannabinoid system, relevant to conditions like migraine and fibromyalgia

Moderate Evidence
12 studies|Most of the evidence came from preclinical studies (in vitro and animal). Only 36 human studies were included, many with small sample sizes. The clinical significance of measured endocannabinoid chang

National survey data showed drug-free workplace policies and EAPs were each associated with 15% lower odds of marijuana use and prescription drug misuse in young workers

Moderate Evidence
12 studies|Cross-sectional design cannot establish causation. People who choose workplaces with drug policies may differ from those who do not. Self-reported drug use and policy awareness. Data from 2004-2008 pr

What We Still Don't Know

  • Long-term prospective studies tracking outcomes over 5+ years are largely absent from the literature.
  • Research on diverse populations (different ages, ethnicities, and medical backgrounds) remains limited.

Evidence Breakdown

Distribution of study types in this research area. Higher-tier evidence (meta-analyses, RCTs) provides stronger conclusions.

Meta-Analyses & Systematic Reviews(Tier 1)
1 (1%)
Randomized Controlled Trials(Tier 2)
7 (9%)
Observational & Cohort(Tier 3-4)
29 (38%)
Reviews & Scoping(Tier 4)
23 (30%)
Other
17 (22%)

Key Studies

The most impactful research in this area.

Exercise consistently raises endocannabinoid levels in the body

The "runner's high" has traditionally been attributed to endorphins, but this research suggests the endocannabinoid system plays a major role in exercise-induced mood elevation and pain relief.

2022

CBD at 50mg or 300mg Did Not Improve or Impair Running Performance in Trained Athletes

Athletes increasingly use CBD for recovery and other health purposes. This rigorous trial provides reassurance that acute CBD use at common doses does not impair performance, while also finding no performance enhancement.

2025

How Long Cannabis Shows Up in Urine — and Why Current Thresholds May Be Wrong

Urine testing is the most common form of cannabis detection in workplaces, criminal justice, and sport — affecting millions of people. This systematic review demonstrates that current thresholds often detect past use rather than recent consumption or impairment. For regular users trying to quit, wee

2026

Occupational medicine guideline says cannabis is not recommended for common workplace injuries and conditions

As legalization expands, employers face pressure to allow cannabis. This provides evidence-based grounds for workplace policies, particularly for safety-sensitive positions.

2025

High-Intensity Exercise Did Not Repair Brain Changes From Cannabis Use Disorder

Exercise has been proposed as a potential treatment for addiction, but this rigorous trial found it did not reverse CUD-related brain changes while people kept using. The strong adherence rate is the silver lining -- it shows people with CUD can commit to structured exercise programs, which could po

2025

CBD Did Not Enhance the Exercise Experience in a Running Trial

CBD is increasingly marketed to athletes. This trial found no enhancement of exercise experience, providing evidence against marketing claims while confirming CBD does not impair exercise.

2024

Research Timeline

How our understanding of this topic has evolved.

2000–2009

3 studies published. Predominantly observational and review studies.

2010–2014

6 studies published. Predominantly observational and review studies.

2015–2019

10 studies published. Predominantly observational and review studies.

2020–present

58 studies published. Includes 1 meta-analyses, 7 RCTs, 7 strong-evidence studies.

About This Consensus

This consensus synthesizes 77 peer-reviewed studies: 1 meta-analyses (1%), 7 randomized controlled trials (9%), 29 observational studies (38%), 23 reviews (30%), 17 other study types (22%). Studies span from the earliest available research through 2025. Evidence strength ratings reflect study design, sample size, and replication across multiple research groups.

This page synthesizes findings from 77 peer-reviewed studies. It is not medical advice. Always consult a healthcare provider for personal health decisions.